MARKET

BJDX

BJDX

Bluejay Diagnostics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.130
+0.010
+0.89%
Closed 19:54 08/10 EDT
OPEN
1.150
PREV CLOSE
1.120
HIGH
1.170
LOW
1.115
VOLUME
33.02K
TURNOVER
--
52 WEEK HIGH
6.25
52 WEEK LOW
0.8150
MARKET CAP
22.77M
P/E (TTM)
-2.7805
1D
5D
1M
3M
1Y
5Y
Blue Water, Leafly top healthcare gainers; ObsEva, Cassava lead losers' pack
Gainers: Blue Water Vaccines BWV +69%. Leafly Holdings (LFLY) <fon...
Seekingalpha · 07/27 14:05
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care ACTON, Mass., July 27, 2022 (GLOBE NEWSWIRE)...
GlobeNewswire · 07/27 11:30
BRIEF-Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
BRIEF-Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
Reuters · 07/26 21:18
Bluejay Diagnostics GAAP EPS of -$0.10, revenue of $249.04M
Bluejay Diagnostics press release (<span class="ticker-hover-wrapper...
Seekingalpha · 07/26 21:00
BRIEF-Bluejay Completes Planned Clinical Studies For Symphony IL-6 Test
BRIEF-Bluejay Completes Planned Clinical Studies For Symphony IL-6 Test
Reuters · 07/06 11:37
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progr...
GlobeNewswire · 07/06 11:30
CLSK, SI and CAN among premarket losers
MicroStrategy MSTR -25% as crypto market cap sinks below $1T. Astra Space ASTR -25% after latest mission failure. Qutoutiao (QTT) -21%. Marathon Digital Holdings MARA -17% as crypto market cap sinks below $1T. Bitfarms BITF -17% as crypto market cap
Seekingalpha · 06/13 12:25
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
More
No Data
Learn about the latest financial forecast of BJDX. Analyze the recent business situations of Bluejay Diagnostics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BJDX stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
High8.00
Average8.00
Low8.00
Current 1.130
EPS
Actual
Estimate
-0.09-0.07-0.04-0.02
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 8
Institutional Holdings: 87.52K
% Owned: 0.43%
Shares Outstanding: 20.15M
TypeInstitutionsShares
Increased
4
24.00K
New
1
15.00K
Decreased
1
7.83K
Sold Out
2
47.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.23%
Healthcare Equipment & Supplies
+2.35%
Key Executives
President, Chief Executive Officer and Director
Neil (Indranil) Dey
Director
Donald R. Chase
Director Nominee
Gary Gemignani
Director
Fred S. Zeidman
Chairman of the Board
Douglas C. Wurth
Chief Technology Officer
Dr. Jason Cook
Chief Commercial Officer
Kevin Vance
Director
Svetlana Dey
Chief Financial Officer
Gordon Kinder
No Data
No Data
About BJDX
Bluejay Diagnostics, Inc. is engaged in the developing medical diagnostics tests devices. The Company offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. Symphony platform is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. The Company is developing a pipeline of diagnostic tests for Symphony, including triage of myocardial infarction (MI), congestive heart failure (CHF), neutropenic sepsis in cancer, and other disease diagnostic indications using the same Symphony platform. The Company's Symphony IL-6 product candidate is for early and rapid identification of sepsis during Emergency Department (ED), critical care triage, and neutropenic sepsis in oncology patients. Symphony IL-6 product candidate is also for monitoring disease progression during such treatment regimen.

Webull offers kinds of Bluejay Diagnostics Inc stock information, including NASDAQ:BJDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BJDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BJDX stock methods without spending real money on the virtual paper trading platform.